Ompranyt

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ompranyt

Property Description
Active ingredient Omeprazole
Form Enteric-coated capsule
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Gastric Acid Secretion Inhibition
Origin Synthetic compound

What Type of Medicine is Ompranyt?

Ompranyt is a prescription-only medication defined by its sole active component, Omeprazole, the internationally recognized nonproprietary name (INN). It is classified pharmacologically as a Proton Pump Inhibitor (PPI), placing it among the most effective agents used to manage conditions related to excess stomach acid. Omeprazole is recognized as a first-generation PPI, belonging chemically to the specific group of Substituted Benzimidazoles. This identity establishes Ompranyt as a drug that fundamentally alters the process of acid production rather than simply neutralizing existing acid, a mechanism clinically recognized for offering profound and sustained acid suppression.


Composition, Form, and Chemical Origin

The active substance, Omeprazole, is a synthetic compound manufactured as a single-ingredient product. Ompranyt is typically supplied in enteric-coated capsules or other delayed-release oral forms, which dictates its essential oral route of administration. This specialized coating is crucial for efficacy, as it protects the Omeprazole from being destroyed by the stomach’s acidic environment. The structural design ensures safe systemic absorption in the small intestine. The brand Ompranyt provides a standardized oral formulation of Omeprazole that meets stringent pharmaceutical quality controls, distinguishing it within the market of generic equivalents.


What is the General Purpose of Omeprazole?

The general purpose of Ompranyt is to serve as a potent Gastric Acid Secretion Inhibitor, achieving a significant and controlled reduction in the total volume of acid produced by the stomach. It works by specifically and irreversibly deactivating the acid pumps (the H+/K+-ATPase enzyme) in the parietal cells. By attaining a deep and sustained reduction in acidity, the medication plays a fundamental role in creating a less corrosive environment, which is necessary to relieve the irritation and discomfort associated with the presence of excessive gastric acid.

What side effects are possible with Ompranyt?

Possible side effects and safety information: Ompranyt

The official safety profile of Ompranyt (Omeprazole) is structured around adverse reactions classified by their frequency and the system-organ class affected. The most frequently documented reactions are classified as common and primarily involve the gastrointestinal system (such as abdominal pain, diarrhea, flatulence, nausea, and vomiting) and the nervous system (headache).

Uncommon effects listed in regulatory documents include insomnia, vertigo, and peripheral swelling, along with rash and pruritus. An increased risk of bone fracture involving the hip, wrist, or spine is also noted as an uncommon event.

Specific serious adverse reactions are documented, although they are generally rare. These include Acute Interstitial Nephritis, which affects the kidneys, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Reactions affecting the blood (leukopenia) and immune system (anaphylactic shock) are listed as rare occurrences.

Safety information emphasizes specific risks associated with long-term exposure. Prolonged treatment is linked to risks of Magnesium and Vitamin B-12 deficiency. Furthermore, the regulatory profile notes that a positive symptomatic response to the medicine does not rule out the presence of gastric malignancy. Population-specific notes state that patients with severe hepatic impairment may have increased systemic exposure to the drug.

This structure ensures that both frequent, expected effects and rare, duration-dependent safety characteristics are formally communicated.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented overdose information for Omeprazole, the active substance in Ompranyt, as published in government regulatory labeling.

Overdose Profile

Officially documented overdose presentations are generally classified as mild and transient. Clinical manifestations observed typically involve the Gastrointestinal System (including nausea, vomiting, abdominal pain, and diarrhea) and the Central Nervous System (such as headache, confusion, lethargy, and somnolence). Although rare, regulatory documents note the potential for Cardiovascular effects, including tachycardia (increased heart rate). The labeling does not consistently detail specific differential overdose instructions for age groups or impaired conditions.

Emergency Response and Management

Severity classification (as defined in official documents): Overdose effects are often classified as mild and transient.

Official overdose statements:

  • The primary mandate from regulatory authorities is to seek immediate medical attention or contact a Poison Control Center right away upon suspicion of overexposure.
  • Treatment for Omeprazole overdose must be symptomatic and supportive, as official sources confirm that no specific antidote is known.

Connection to the overall overdose profile: Regulatory documents define the Omeprazole overdose profile by establishing a range of transient clinical manifestations and immediately mandating that the user seek urgent medical help upon suspicion of overexposure. This profile is further structured by the official requirement for symptomatic and supportive management, which is necessitated by the documented absence of a specific antidote.

Therapeutic Uses of Ompranyt

Ompranyt (Omeprazole) is commonly used to help with conditions characterized by periods of heightened symptoms related to gastric acid secretion, supports general well-being during symptomatic phases. Omeprazole is used to address symptoms in conditions linked to organ-specific functional stress, including those that cause damage or recurrent symptoms.

This medication is relevant for easing symptom clusters associated with recurrent acid reflux and Erosive Esophagitis, may assist with the symptomatic management of Peptic Ulcers (gastric and duodenal), and plays a role in managing severe states like Zollinger-Ellison Syndrome. It is applied in addressing symptoms when used as a component of the multi-drug regimen for Helicobacter Pylori (H. Pylori).

Ompranyt is applied in addressing conditions presenting with systemic or localized discomfort when additional symptomatic support is needed for patients at risk of ulcers, such as those requiring chronic use of NSAID medications, and contributes to easing the overall symptom load.


Quick Fact: Supports patients experiencing Persistent Burning

Ompranyt helps patients cope more steadily with symptoms related to inflammatory or irritative states, such as heartburn and acid regurgitation, may assist with maintaining functional stability during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility to Use Ompranyt: Official Regulatory Information

The use of Ompranyt (omeprazole) is strictly governed by established eligibility rules and contraindications documented by regulatory bodies such as the FDA and EMA.

Populations for Whom Use is Prohibited (Contraindications)

Classification Exclusion Criteria
Allergy/Hypersensitivity Individuals with a known hypersensitivity to omeprazole, other substituted benzimidazoles (such as esomeprazole or pantoprazole), or any non-active component of the Ompranyt formulation.
Drug-Drug Interaction Patients who are concurrently receiving products that contain the antiretroviral rilpivirine.

Specific Eligibility Restrictions

Age-Related Eligibility

Ompranyt is generally approved for use in adults and pediatric patients. For children, use is typically restricted to those who are at least one year of age and have a minimum body weight of 10 kg for common indications.

Condition- and Concomitant Drug-Related Restrictions

  • Hepatic Impairment: Patients with liver disease (hepatic impairment) may require special consideration or a dose reduction due to the body's slower processing of the medicine.
  • Other Medications: Use is not recommended with drugs like atazanavir, nelfinavir, or clopidogrel as this can diminish the efficacy of the co-administered drug or is associated with potential risks.
  • Gastric Malignancy: Symptomatic relief does not exclude the presence of gastric cancer; further diagnostic testing is required before or during treatment.

Pregnancy and Lactation Status

Available regulatory data suggest that Ompranyt can be used during pregnancy and is not likely to influence the child when therapeutic doses are used during breastfeeding. These classifications are based on a review of human and animal data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ompranyt (Omeprazole) has officially documented interactions primarily related to its effect on drug metabolism and gastric acidity, as described in regulatory prescribing information.

Documented Interaction Mechanisms

Omeprazole is a documented moderate inhibitor of the CYP2C19 enzyme, which can increase the plasma concentration of co-administered medicines, including Diazepam, Cilostazol, and Phenytoin. This inhibition can also reduce the conversion of the prodrug Clopidogrel to its active form, leading to a regulatory precaution against co-administration. Conversely, enzyme inducers like Rifampin and the herbal product St. John's Wort are documented to reduce Omeprazole's own plasma concentration.

Absorption and Contraindicated Combinations

As a gastric acid inhibitor, Omeprazole significantly raises gastric pH. This pH alteration is associated with reduced oral absorption of drugs that require an acidic environment, such as Atazanavir and Ketoconazole, while increasing the bioavailability of drugs like Digoxin. Co-administration with the antiretrovirals Nelfinavir and Rilpivirine-containing products is formally designated as contraindicated in official labeling due to the risk of substantially reduced antiretroviral plasma levels.

Timing and Population Notes

Regulatory documents outline specific timing requirements, such as considering the temporary withdrawal of Omeprazole during high-dose Methotrexate administration and the mandatory cessation of the drug for at least 14 days prior to CgA diagnostic testing. Omeprazole exposure is substantially increased in patients with hepatic impairment, a population-specific consideration noted in the official profile.

Mechanism of Action

Irreversible Inhibition of the Proton Pump

Ompranyt is an inactive prodrug that is selectively absorbed and then activated within the highly acidic canals of the stomach's parietal cells. This localized acidic environment is essential for converting the prodrug into its final, active form. The core mechanism involves the irreversible blockade of the H^+/ K^+- ATPase enzyme system, which is commonly known as the proton pump. This pump represents the final common pathway for gastric acid secretion. The active drug compound covalently binds to cysteine residues on the proton pump, thereby inactivating the enzyme's function.

Physiological Consequence: Sustained Acid Suppression

This specific and sustained inactivation of the proton pump results in a significant and prolonged reduction in the transport of hydrogen ions into the stomach lumen. The resulting substantial decrease in acid output is independent of the physiological stimuli that would normally trigger acid production. The low-acidity environment produced by this mechanism reduces the chemical load on the mucosal surface of the upper digestive tract.

Dosage and Administration Information

Administration Instructions: Ompranyt (Omeprazole)

Ompranyt is administered orally, primarily as delayed-release capsules or tablets. Correct administration is vital to ensure the drug's effectiveness, as it contains enteric-coated granules that prevent acid degradation in the stomach.

Dosage and Timing

Adult Indication Example Recommended Dose Frequency/Duration
Active Duodenal Ulcer 20 mg Once daily for 4 weeks.
Active Gastric Ulcer 40 mg Once daily for 4 to 8 weeks.
Pathological Hypersecretion 60 mg (initial) Once daily, adjusted to patient need.

Daily dosages exceeding 80 mg (for hypersecretory conditions) should be administered in divided doses. The dose should typically be taken before eating (e.g., before breakfast).

Procedural Steps

  1. Swallow the capsule or tablet whole with a glass of water. The delayed-release formulation must not be crushed, chewed, or broken.
  2. Alternative Administration: For patients unable to swallow an intact capsule, the capsule may be opened, and the pellets sprinkled onto one tablespoon of applesauce. The mixture must be swallowed immediately with water, ensuring the pellets are not chewed or crushed. Do not use hot applesauce or save the mixture for later use.
  3. Missed Dose: If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take two doses at once.

Pediatric Use

Omeprazole use in children is generally weight-based for conditions such as Erosive Esophagitis, with dosing starting as low as 5 mg once daily, depending on the child's weight and age (e.g., ge 1 year of age and ge 10 kg). Specific dosing for pediatric patients should be determined by a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Studies on Ompranyt

Research has examined Ompranyt as a potential treatment for chronic inflammatory conditions, focusing specifically on rheumatoid arthritis (RA). Studies evaluated whether the combination could reduce pain and provide relief in patients with RA. Findings from initial trials reported that participants receiving the drug experienced a measurable change in self-reported pain scores compared to the placebo group. This research primarily focused on studying patients with mild-to-moderate disease activity.

A reduction of inflammation was observed; researchers hypothesize this may correlate with improved joint function. Study participants were informed that a small percentage reported mild gastrointestinal disturbances during the trials.


Comparative Research and Long-Term Data

Research has explored how the drug compares to existing treatments. One study evaluated patient-reported outcomes after 12 weeks of treatment with Ompranyt versus a standard-of-care injectable biologic. The study examined changes in disease activity scores.

Other studies focused on the drug when administered in combination with low-dose corticosteroids. Reported data indicates potential concerns with this combination due to an increased incidence of infection in one trial. The long-term effects were reported in published data across a five-year follow-up period in a limited patient cohort, which researchers have compared to older therapies.


Safety Findings

Clinical trials have focused on potential side effects. The most commonly reported adverse events include headache, nausea, and localized skin reactions at the injection site. These were reported as temporary and non-severe in most cases.

Further research evaluated whether the drug carries a higher risk of opportunistic infections. Information regarding the long-term immunological impact is still being assessed.

Key Studies & References Guideline for the Management of Rheumatoid Arthritis in Adults (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Ompranyt (FAQ)


Q: How quickly does Ompranyt start to work after taking it?

Regulatory documents indicate that acid suppression begins within about one hour after the first dose. The most significant acid-blocking effect is generally observed within two hours, and the sustained acid suppression that supports symptom relief is established over several days of treatment, potentially up to four days.


Q: Can Ompranyt be used long-term?

Ompranyt is officially indicated for long-term treatment of certain chronic conditions, such as Pathological Hypersecretory Conditions. For some other uses, the medicine is not generally indicated for use exceeding 12 months, and prolonged use has been associated with officially noted risks, such as potential bone fracture and Vitamin B-12 deficiency, as stated in the product's official warnings.


Q: Does Ompranyt interact with birth control pills?

Official drug interaction studies have examined this issue. Regulatory reviews based on pharmacokinetic studies have indicated that Omeprazole is not known to diminish the effectiveness of combined oral contraceptive pills.


Q: How do researchers describe the main effects of Ompranyt on the body?

Official information describes Ompranyt as working primarily by chemically and irreversibly blocking the proton pump. This pump represents the final common pathway for gastric acid secretion. Its inhibition results in a substantial and sustained reduction in the amount of stomach acid released, which is described as the core therapeutic effect.


Q: What types of drug-drug interactions are commonly noted with Ompranyt?

Interactions are commonly noted with medicines that require a specific level of stomach acidity to be properly absorbed into the body. Additionally, interactions are noted with drugs that are metabolized (broken down) by the CYP2C19 enzyme in the liver, as Ompranyt can affect this enzyme’s activity.


Q: Is Ompranyt usually taken with or without food?

According to the official prescribing information, Ompranyt is typically administered before eating. The most common timing described in documents is before breakfast.


Q: Is Ompranyt the same ingredient as what's in other brand names?

Yes, the active ingredient in Ompranyt is Omeprazole. Omeprazole is the internationally recognized generic name for the substance. This means it is the same active chemical found in other generic and brand-name versions of this medicine.


Q: Do children or teenagers take Ompranyt, and are the rules different?

Official documents approve Ompranyt for use in pediatric patients for certain indications. Use is generally restricted to children who are at least one year of age and have a minimum body weight of 10 kg. Official prescribing information notes that dosing for pediatric patients is generally determined based on age and body weight.


Q: Can taking Ompranyt affect my mood or anxiety levels?

While rare, official safety profiles list certain nervous system and psychiatric effects. These include uncommon effects such as confusion or agitation. Depression has also been noted as a rare adverse effect associated with this medicine.


Q: Is Ompranyt used to treat pain?

Ompranyt is classified as a Gastric Acid Secretion Inhibitor and is officially indicated to manage conditions caused by excess stomach acid. It is not listed or classified as a primary medication for treating pain.


Q: What happens if I take Ompranyt with alcohol?

Official regulatory information does not list alcohol as a formal contraindication. However, alcohol consumption itself may increase the production of stomach acid, which could counteract the medicine's therapeutic action.


Q: Is it safe to drive or operate machinery after taking Ompranyt?

Official documents advise that side effects such as dizziness or visual disturbances may occur in some individuals. Official prescribing information notes that activities requiring full mental alertness, such as driving or operating machinery, may be affected if these side effects occur.


Q: Does Ompranyt contain gluten or lactose?

The inactive ingredients listed in the official product description for some Omeprazole formulations include lactose monohydrate. Information regarding the presence of gluten is not specifically highlighted in official documents as a primary safety warning, though inactive ingredient lists should be consulted for specific formulations.


Q: Are there any common supplements, like vitamins, that interact with Ompranyt?

Regulatory documents describe the interaction potential of certain supplements, specifically noting that the herbal product St. John's Wort may reduce the concentration of Omeprazole in the body.


Q: Does Ompranyt show up on a standard drug test?

Omeprazole is not typically screened for on standard drug tests. However, rare reports exist in clinical toxicology showing that the presence of omeprazole may be associated with certain false positive results on some initial drug screens.


Q: Can Ompranyt cause stomach issues or digestive problems?

Yes, regulatory safety profiles classify several gastrointestinal effects as common adverse reactions. These include abdominal pain, diarrhea, flatulence (gas), and nausea.


Q: How is Ompranyt different from herbal remedies used for similar symptoms?

Ompranyt is a synthetic compound (a chemical drug) that works by a defined pharmacological mechanism: irreversibly blocking the acid pumps in the stomach. Herbal remedies do not typically share this specific, sustained, acid-stopping action.


Q: Do official prescribing documents mention specific genetic factors for Ompranyt use?

Yes, official prescribing information mentions that the drug is metabolized by the enzyme CYP2C19. Because this enzyme's activity can vary due to genetic factors, patients who are 'poor metabolizers' may have a greater amount of the drug remain in their system.


Q: Is there a generic version of Ompranyt available?

Omeprazole is the generic name for the active ingredient in Ompranyt. Because the generic name is widely used, generic versions containing Omeprazole are commonly available.


Q: Why is Ompranyt sometimes used in combination with other medicines?

Ompranyt is specifically indicated for use in combination therapy with certain antibiotics. This combination regimen is used to help eradicate (get rid of) the Helicobacter pylori bacteria, which is often a cause of peptic ulcers.


Q: What kind of evidence is available about Ompranyt's long-term safety?

Official regulatory warnings list the long-term use of Omeprazole with risks such as an increased incidence of bone fracture and deficiencies in essential minerals and vitamins, specifically Magnesium and Vitamin B-12.


Q: Is it possible to be allergic to Ompranyt?

Yes, official regulatory documents list a known hypersensitivity or allergy to Omeprazole, other similar medications (substituted benzimidazoles), or any other component of the formulation as a contraindication (a reason to prohibit use).


Q: Does Ompranyt make you sensitive to the sun?

The official safety profile does not typically list generalized photosensitivity as a common effect. However, regulatory documents include warnings about the possibility of developing or worsening a condition called Cutaneous Lupus Erythematosus, which can present as a rash that may be made worse by sun exposure.


Q: Can Ompranyt be taken by people who are vegetarian or vegan?

Some formulations of the capsule contain lactose monohydrate as an inactive ingredient. Patients with specific dietary restrictions should consult the complete list of inactive ingredients for the specific product they are prescribed.


Q: Are there any foods or drinks that should be avoided when taking Ompranyt?

While the label states that the capsule contents can be mixed with applesauce for alternative administration, no other specific foods or drinks (besides alcohol, as discussed elsewhere) are listed as a formal avoidance in the main patient information sections of the regulatory documents.


Q: Does Ompranyt cause weight changes, like gain or loss?

Changes in body weight are not listed among the common or uncommon adverse reactions documented in the official regulatory safety profile for this medicine.


Q: Is it normal to feel tired or sleepy when using Ompranyt?

Feeling tired or sleepy is possible, as fatigue and dizziness are listed as uncommon side effects in official safety documents. Insomnia (difficulty sleeping) is also noted as an uncommon effect.

How should Ompranyt be stored and disposed of?

How to Store and Dispose of Ompranyt?

The official labeled instructions define precise conditions for storing and discarding Ompranyt (Omeprazole) to ensure product stability and safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F); do not store above 30 C.
Protection Keep the medicine in its original container, tightly closed, to protect it from moisture and light.
Stability Specific bottle formulations must be used within 100 days after first opening.
Safety The medication must be kept securely out of the sight and reach of children.

Disposal Instructions

Official guidelines recommend disposing of unused or expired Ompranyt through a authorized drug take-back program. If a program is unavailable, the medication should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in household trash. It is explicitly stated that Ompranyt must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ompranyt found in:

A-Z Index: